pipeline Archives -

With record-breaking revenues and profits accruing on the back of its COVID-19 products, Pfizer is planning a big

Pfizer heading for purple patch of in-house product launches

https://pharmaphorum.com/news/pfizer-heading-for-purple-patch-of-in-house-product-launches/

FDA knocks back Takeda’s blockbuster hope TAK-721

Phil Taylor eosinophilic oesophagitis, Immunology and inflammation, pipeline, Takeda 0 Comment

Japanese drugmaker Takeda has suffered a blow to its late-stage pipeline, after the FDA rejected its marketing application

FDA knocks back Takeda’s blockbuster hope TAK-721

https://pharmaphorum.com/news/fda-knocks-back-takedas-blockbuster-hope-tak-721/

News/ News/ R&D

GSK sees £20bn peak sales potential in late-stage pipeline

Phil Taylor Blenrep, consumer health, Emma Walmsley, GlaxoSmithKline, M&A, mRNA, pipeline, respiratory syncytial virus, vaccine 0 Comment

GlaxoSmithKline’s pitch to shareholders kicked off this afternoon with an optimistic view of its late-stage pipeline – including

GSK sees £20bn peak sales potential in late-stage pipeline

https://pharmaphorum.com/news/gsk-sees-20bn-peak-sales-potential-in-late-stage-pipeline/

News/ News/ Oncology

Genmab axes development of AXL-targeting cancer drug enapotamab vedotin

Richard Staines BerGenBio, cancer, Genmab, pipeline, R&D 0 Comment

Genmab has axed development of its pipeline cancer drug enapotamab vedotin after it failed to show enough activity

Genmab axes development of AXL-targeting cancer drug enapotamab vedotin

https://pharmaphorum.com/news/genmab-axes-development-axl-targeting-cancer-drug-enapotamab-vedotin/

News/ News/ R&D/ Top stories

Novartis set to overcome $14 billion patent cliff say analysts

Richard Staines biosimilars, cancer, inflammatory diseases, Novartis, pipeline, R&D, Sandoz 0 Comment

Novartis’ pipeline is strong enough to overcome a $14 billion patent cliff as blockbuster drugs face generic competition

Novartis set to overcome $14 billion patent cliff say analysts

https://pharmaphorum.com/news/novartis-set-to-overcome-14-billion-patent-cliff-analyst/

Close-up image of a firm handshake between two colleagues

News/ News/ News/ News/ Oncology/ R&D/ Sales and Marketing

AstraZeneca ‘probably couldn’t run Gilead any better:’ analyst

Phil Taylor AstraZeneca, Gilead Sciences, M&A, Oncology, pipeline 0 Comment

AstraZeneca and Gilead are both staying tight-lipped over rumoured merger talks, but the consensus among analysts seems to

AstraZeneca ‘probably couldn’t run Gilead any better:’ analyst

https://pharmaphorum.com/news/astrazeneca-probably-couldnt-run-gilead-any-better-analyst/

News/ News/ Oncology

AZ reportedly mulls biggest-ever pharma merger with Gilead

Richard Staines AstraZeneca, COVID-19, Gilead, infectious diseases, M&A, Oncology, pipeline 0 Comment

Almost exactly six years ago AstraZeneca managed to convince investors to reject a takeover bid from Pfizer –

AZ reportedly mulls biggest-ever pharma merger with Gilead

https://pharmaphorum.com/news/az-reportedly-mulls-biggest-ever-pharma-merger-with-gilead/

News/ News/ R&D

NodThera raises $55m in Series B round to trial inflammatory disease drugs

Richard Staines Biotech, Funding, inflammatory diseases, NodThera, pipeline, R&D 0 Comment

The Anglo-US biotech NodThera has raised $55 million in a second financing round as it prepares its inflammatory

NodThera raises $55m in Series B round to trial inflammatory disease drugs

https://pharmaphorum.com/news/nodthera-raises/

News/ News/ R&D/ Top stories

Failed trial puts future of UCB’s epilepsy drug padsevonil in doubt

Phil Taylor central nervous system, epilepsy, pipeline, UCB 0 Comment

Shares in UCB slid this morning after the Belgian company announced its refractory epilepsy drug candidate padsevonil had

Failed trial puts future of UCB’s epilepsy drug padsevonil in doubt

https://pharmaphorum.com/news/failed-trial-puts-future-of-ucbs-epilepsy-drug-padsevonil-in-doubt/

Trending

pipeline

Login